David Rosmarin (D Rosmarin)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 24

Top Topics

Atopic Dermatitis

Top Venues

Dermatology and therapy

American journal of clinical dermatology

Journal of the European Academy of Dermatology and Venereology : JEADV

The British journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

David Rosmarin, Jennifer H Lofland, Simran Marwaha, James Piercy, Peter Anderson, Jinan Liu
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients. Dermatology and therapy 14 (6) (2024)
David Rosmarin, Jennifer H Lofland, Simran Marwaha, James Piercy, Peter Anderson, Jinan Liu
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients. Dermatology and therapy 14 (6) (2024)
Thierry Passeron, John E Harris, Amit G Pandya, Julien Seneschal, Pearl Grimes, Deanna Kornacki, Mingyue Wang, Khaled Ezzedine, David Rosmarin
Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
David Rosmarin, Ahmed M Soliman, James Piercy, Simran Marwaha, Peter Anderson, Heidi S Camp
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location. Dermatology and therapy 14 (6) (2024)
David Rosmarin, Jennifer H Lofland, Simran Marwaha, James Piercy, Peter Anderson, Jinan Liu
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients. Dermatology and therapy 14 (6) (2024)
David Rosmarin, Ahmed M Soliman, James Piercy, Simran Marwaha, Peter Anderson, Heidi S Camp
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location. Dermatology and therapy (2024)
Jennifer H Lofland, Samyuktha Darbha, Ahmad B Naim, David Rosmarin
Healthcare Resource Use and Costs Among Individuals with Vitiligo and Psychosocial Comorbidities: Retrospective Analysis of an Insured US Population. ClinicoEconomics and outcomes research : CEOR 16 (2024)
David Rosmarin, Jennifer H Lofland, Simran Marwaha, James Piercy, Peter Anderson, Jinan Liu
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients. Dermatology and therapy (2024)
David Rosmarin, Ahmed M Soliman, James Piercy, Simran Marwaha, Peter Anderson, Heidi S Camp
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location. Dermatology and therapy 14 (6) (2024)
David Rosmarin, Jennifer H Lofland, Simran Marwaha, James Piercy, Peter Anderson, Jinan Liu
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients. Dermatology and therapy 14 (6) (2024)
David Rosmarin, Ahmed M Soliman, James Piercy, Simran Marwaha, Peter Anderson, Heidi S Camp
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location. Dermatology and therapy 14 (6) (2024)
Jennifer H Lofland, Samyuktha Darbha, Ahmad B Naim, David Rosmarin
Healthcare Resource Use and Costs Among Individuals with Vitiligo and Psychosocial Comorbidities: Retrospective Analysis of an Insured US Population. ClinicoEconomics and outcomes research : CEOR 16 (2024)
David Rosmarin, Ahmed M Soliman, James Piercy, Simran Marwaha, Peter Anderson, Heidi S Camp
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location. Dermatology and therapy 14 (6) (2024)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology 24 (2) (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology 24 (2) (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology (2023)
Kaitlynne N Cunningham, Sarah Alsukait, S R Cohen, C Learned, D X Gao, C Kachuk, N Dumont, A Zipeto, David Rosmarin
Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kaitlynne N Cunningham, Sarah Alsukait, Stephanie R Cohen, Christine Learned, David X Gao, Courtney Kachuk, Nicole Dumont, Alysha Zipeto, David Rosmarin
Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Kaitlynne N Cunningham, David Rosmarin
Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. American journal of clinical dermatology 24 (2) (2023)
Christine Learned, Sara Alsukait, Kristin R Fiumara, Melissa Ortega, James D Chambers, David Rosmarin
Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. Journal of psoriasis and psoriatic arthritis 7 (4) (2022)
Nujood Abdulwahed Alzahrani, J Grossman-Kranseler, Ritu N Swali, K Fiumara, P Zancanaro, S Tyring, David Rosmarin
Hailey-Hailey disease treated with dupilumab: a case series. The British journal of dermatology 185 (3) (2021)
Maria C Schneeweiss, J F Merola, S Schneeweiss, R Wyss, David Rosmarin
Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (1) (2020)
R Reddy, S Pannu, K Fiumara, J Kahn, David Rosmarin
Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment. The British journal of dermatology 184 (3) (2020)
Andrew Blauvelt, David Rosmarin, T Bieber, E L Simpson, J Bagel, M Worm, Mette Deleuran, N Katoh, M Kawashima, B Shumel, Z Chen, A B Rossi, T Hultsch, M Ardeleanu
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. The British journal of dermatology 181 (1) (2019)